Botulinum Toxin In Management Research Articles

Botulinum toxin in management of back pain

Botulinum toxin in management of back pain

The role of botulinum toxin in management of infantile esotropia

Purpose: To find out the effect of a single dose botulinum toxin injection. Methods: This study is an observational case series. Data of patients with infantile esotropia who received a single dose of botulinum toxin in 6th-9th month of their age were retrospectively reviewed during the period from February 2013 to January 2015. Botulinum toxin was injected in each of medial recti with a dose of 5 IU/0,05 mL without Electromyography (EMG) control. Five patients were included in the study. Complications reletad to injection and to the toxin were recorded. During their regular follow-ups, the parents were instructed to patch the dominant eye if there is fixation preference either in exotropia or esotropia phases. Patients were examined between their 72nd to 96th month to find out their current visual acuity and to observe if they had any late term accompanying squints, nystagmus and amblyopia. Snellen optotypes or pictures were used for detecting best-corrected visual acuity. Results: Orthophoria was the main outcome for 3 of the 5 patients. Dissociated deviations and latent nystagmus did not develop on any patient. On the last examination, patients’ visual acuities were assesed. Orthophoric ones: One patient had 1.0/1.0 visual acuity, one patient had 0.4/0.6 visual acuity, one patient had 0.2/0.2 visual acuity. Monocular esotropia ones: On the strabismic eye 0.1, on the dominant eye 1.0 visual acuity was detected. Inferior oblique muscle hyperfunction developed post injection on all the patients. Conclusions: Botulinum toxin injection caused infantile esotropia to change into a more manageble form.

Early Use of Phenol Neurolysis Likely Reduces the Total Amount of Botulinum Toxin in Management of Post-Stroke Spasticity.

The main objective was to examine practice patterns of phenol neurolysis for post-stroke spasticity management in the early stage. We performed a chart review of patients who were admitted for inpatient rehabilitation within 6 months after first-ever stroke and received phenol neurolysis within 15 months post-stroke. Out of 2,367 stroke admissions from January 2014 and December 2018, 68 patients met the criteria. 52.9% of these patients received phenol neurolysis within 12 weeks, i.e., early stage. The earliest phenol neurolysis procedure was at 19 days after stroke. On average, patients received first phenol injections at 16.3 weeks after stroke with an average dose of 7.3 ml. Most commonly injected nerves were tibial nerve motor branches (41/68), sciatic nerve motor branches (37/68), lateral pectoral nerve (16/68), medial pectoral nerve (15/68), obturator nerve (15/68) and musculocutaneous nerve (15/68). Among 68 patients, 24 received phenol only; 17 received phenol neurolysis first followed by botulinum toxin (BoNT) injections; 19 received BoNT injections first followed by phenol neurolysis; 8 received both phenol and BoNT injections at the same time. The interval from stroke to first procedure was similar between the Phenol-First group (13.3 weeks) and the BoNT-First group (12.6 weeks). The total amount of BoNT was significantly lower in the Phenol-First group (361.3 units) than in the BoNT-First group (515.8 units) (p = 0.005). The total amount of phenol was not statistically different between the Phenol-First group (5.9 ml) and the BoNT-First group (8.3 ml). The interval between the first procedure and its subsequent procedure was not statistically different between the Phenol-First group (18.3 weeks) and the BoNT-First group (10.7 weeks). These long intervals suggest that the subsequent injection (type and dose) was not planned during the first procedure. The general patterns of target areas were similar between BoNT injections and phenol neurolysis, except that phenol neurolysis rarely targeted the upper extremity distal muscles. No side effects after phenol or BoNT injections in the early stage after stroke were observed in the chart review. In summary, phenol neurolysis was started as early as 19 days after stroke. On average, patients received first phenol about 4 months after stroke with an average of 7.3 ml of phenol. Early use of phenol neurolysis likely decreases the total amount of BoNT for management of post-stroke spasticity without increased side effects.

Efficacy and safety of botulinum toxin for management of hypertrophic scars: a systematic review and meta-analysis

Efficacy and safety of botulinum toxin for management of hypertrophic scars: a systematic review and meta-analysis

Botulinum toxin in management of synkinesis in patients with unilateral and bilateral vocal fold paralysis.

The LaryngoscopeVolume 128, Issue 2 p. 447-450 Laryngology Botulinum toxin in management of synkinesis in patients with unilateral and bilateral vocal fold paralysis Sean Lewis MD, Corresponding Author Sean Lewis MD seanlewis210@gmail.com orcid.org/0000-0002-8800-6671 Department of Otolaryngology, Mount Sinai Hospital, New York, New York, U.S.ASend correspondence to Sean Lewis, MD, 1 Gustave Levy Place, Box 1189, New York, NY 10029. E-mail: seanlewis210@gmail.comSearch for more papers by this authorPeak Woo MD, Peak Woo MD Department of Otolaryngology, Mount Sinai Hospital, New York, New York, U.S.ASearch for more papers by this author Sean Lewis MD, Corresponding Author Sean Lewis MD seanlewis210@gmail.com orcid.org/0000-0002-8800-6671 Department of Otolaryngology, Mount Sinai Hospital, New York, New York, U.S.ASend correspondence to Sean Lewis, MD, 1 Gustave Levy Place, Box 1189, New York, NY 10029. E-mail: seanlewis210@gmail.comSearch for more papers by this authorPeak Woo MD, Peak Woo MD Department of Otolaryngology, Mount Sinai Hospital, New York, New York, U.S.ASearch for more papers by this author First published: 29 August 2017 https://doi.org/10.1002/lary.26839Citations: 6 Presented at the Triological Society Combined Sections Meeting, New Orleans, Louisiana, U.S.A., January 19–21, 2017. The authors have no funding, financial relationships, or conflicts of interest to disclose. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume128, Issue2February 2018Pages 447-450 RelatedInformation

Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair

Botulinum toxin is a neurotoxin that has been utilized to induce chemo-denervation of muscles. Cutaneous wounds represent a special situation in which the tensile forces applied by these muscles on wound edges might have deleterious effects on the healing process. The aim of this review was to investigate such an effect and to review other mechanisms this toxin might have on the healing process. We also reviewed the role of botulinum toxin in the management of hypertrophic scars and cleft lip repair.

The use of botulinum toxin in the management of convergence insufficiency exotropia

Convergence insufficiency is a common condition in which there is a failure to converge for close work, with exotropia at near. Various surgical and nonsurgical treatments have been described, but some patients remain symptomatic despite treatment. The role of botulinum toxin in strabismus management is well established, but its use in the treatment of convergence insufficiency has not been previously reported.

The role of botulinum toxin in management of pain: an evidence-based review

In the present review we discuss the role of botulinum neurotoxins (BoNTs) in the management of different pain conditions, with evidence-based data on the toxins' efficacy on pain and its mechanisms. Experimental in-vitro studies have reported promising results of a novel recombinant chimera of BoNT A and E that inhibits the calcitonin gene-related peptide exocytosis from brainstem sensory neurons. Animal studies in neuropathic pain rat models have reported an analgesic effect of BoNT A given after the neuropathic procedure and a bilateral antinociceptive effect to the unilateral noxious stimuli. There is a growing body of evidence that BoNTs are effective in myofascial pain syndrome, neuropathic pain, and joint pain. The pre-existing evidence that BoNTs are ineffective in migraine or other headache disorders has not yet been challenged. In other pain syndromes, studies published in the last review year have not contributed significantly in either demonstrating or invalidating the research that has so far proved inconclusive. The role of BoNTs in management of pain is not yet well established. Larger studies in neuropathic pain, joint pain, and myofascial pain syndrome are needed to fully ascertain the role for BoNT therapy in those areas.

The role of Botulinum toxin in management of acute traumatic third-nerve palsy

To study the effect of botulinum toxin A injection in the management of paralytic exotropia resulting from acute traumatic third (oculomotor) nerve palsy. Nine patients with acute traumatic partial third-nerve palsy of less than 2 months' duration were treated by injection of botulinum toxin A into the ipsilateral lateral rectus muscle. The horizontal deviation angles before and after the injections were recorded. A distance exotropia of less than 10(Delta) or absence of diplopia in the primary position at the last follow-up was defined as recovery. The mean preinjection deviation in the primary position was 48.3(Delta) of exotropia, and the mean postinjection deviation in the primary position was 14.2(Delta) at the last follow-up. Seven patients experienced recovery and regained single binocular vision in the primary position. The overall recovery rate was 77.8%. Two patients did not recover and subsequently underwent strabismus surgery. Patients with acute traumatic partial third-nerve palsy treated by injection of botulinum toxin A in the lateral rectus muscle showed marked recovery when injection was performed within 2 months of the onset of palsy. Botulinum toxin injection into the lateral rectus muscle may provide temporary relief of symptoms in some patients and seems to be a useful treatment option in cases of acute traumatic third nerve palsy in the short-term.

Botulinum toxin in management of neuroma pain: case report

AbstractNeuroma is a painful condition and always a challenging situation for pain clinicians. Botulinum toxin (BoNT) is a neurotoxin and it provides analgesia, possibly by inhibiting acetylcholine release or blocking autonomic pathways. We report two interesting cases of neuroma in which botulinum toxin (BoNT) serotype-A was locally infiltrated (10 units into the trigger point), three times after an interval of one month each. We observed relief of pain after 10 days and a complete remission after 4 months.

141. A Very Low Dose of Botulinum Toxin in Management of Spasticity in Thai Cerebral Palsied Children at Chulalongkorn University Hospital A. Anannontsak (Bangkok, Thailand

141. A Very Low Dose of Botulinum Toxin in Management of Spasticity in Thai Cerebral Palsied Children at Chulalongkorn University Hospital A. Anannontsak (Bangkok, Thailand